The Investor Globe

  Home   |  Business   |  Personal Finance   |  Gold   |  World   |  USA   |  China   |  India   |  Middle East   |  Bitcoin   |  Techno   |  Blogs   |  M & A   |  IPO

Top Stories on Genentech

Genentech Reports Second Positive Study of ACTEMRA Given by Subcutaneous Injection to Patients with Rheumatoid Arthritis - Bloomberg

Genentech Reports Second Positive Study of ACTEMRA Given by Subcutaneous Injection to Patients with Rheumatoid Arthritis ? Data Will Be Submitted to the FDA for ACTEMRA Subcutaneous Formulation ? Business Wire SOUTH SAN FRANCISCO, Calif.

Genentech Remains Image Leader among Oncologists; Novartis Edges Out Lead among Hematologists - Bloomberg

Genentech Remains Image Leader among Oncologists; Novartis Edges Out Lead among Hematologists PR Newswire LIVONIA, Mich., July 24, 2012 LIVONIA, Mich., July 24, 2012 /PRNewswire/ -- Genentech and Novartis have the best image among oncologists ...

Genentech's Lucentis recommended for approval for diabetic eye disease - The Business Journal

An FDA advisory panel recommended Thursday that Genentech Inc.'s eye drug Lucentis be approved for some diabetes patients who have lost their sight. Already approved for age-related macular degeneration, Lucentis' approved use could extend to ...

Genentech's Lucentis restores diabetic vision loss, FDA says - The Business Journal

Genentech Inc.'s eye drug Lucentis improved the vision of people with a type of blindness associated with diabetes, drug regulators said in a report Tuesday, according to the news agency Bloomberg. The report came in advance of a Food and Drug ...

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint - News-Medical.Net

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the BREVACTA study of ACTEMRA (tocilizumab) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

Genentech's BREVACTA study of ACTEMRA meets primary endpoint - pharmabiz.com

Genentech, a member of the Roche Group, has reported that BREVACTA study of ACTEMRA (tocilizumab) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint. After 24 weeks of treatment, RA patients who ...

Genentech Partnering 2005-2012 - new company profile report - Transworld News

This report provides all the information you require to better understand Genentech and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the ...

UPDATE 2-US advisers back Roche drug for diabetic eye condition - CNBC

Lucentis, which is made by Roche unit Genentech and administered by monthly injection, is already approved for two other eye ailments. Shares in Roche closed slightly higher at 168 Swiss francs before the panel reached its recommendations. There are ...
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
/script>
 

/script>
 
Blogspot logo    Latest Posts from Jim Rogers blog
Focus On Stocks That Are Not On The ETFs Radars
When The Bear Market Arrives...
The US Dollar Will Lose The Currency Reserve Status Fast
Investing: How To Be Successful
Gold Will Eventually Have An Epic Move Up
 
Blogspot logo    Latest Posts from Felix Zulauf blog
Felix Zulauf: Japan Will Be the Root Cause of the Next Global Crisis
Felix Zulauf Readies Hedge Fund With Son
FELIX ZULAUF: Stocks Remind Me Of Gold And They Could See A 'Quick And Painful Adjustment'
Felix Zulauf Recommended 7 Trades At Barron's Roundtable
Felix Zulauf's Yen for Japan
 
  Latest Posts from Mad Money 
Cramer?s Exec Cut: The benefits and dangers of advancing technology
Cramer Remix: The 2 distinct places investors should keep their cash
Cramer makes the bull case for including bonds in your portfolio
Cramer shares the best way to get your child excited about investing
Cramer: How compounding can help you double your money in 7 years
 
   Latest Posts from Fast Money
'Ugly correction' coming: Dennis Gartman
Your first trade for Tuesday
Retail terrified by EEM: Pro
Stock Pops & Drops: AOL, FEYE, JOSB & RYAAY
Second leg of bond rally: Pro
 
 Latest Posts from Bill Cara blog
Tables & Charts for Wednesday, Apr 17th, 2013
Bill Cara's Blog for Apr 17, 2013
Tables & Charts for Tuesday, Apr 16th, 2013
Bill Cara's Blog for Apr 16, 2013
Tables & Charts for Monday, Apr 15th, 2013
 
logo    Latest Posts from Kirk Report

Warning: MagpieRSS: Failed to parse RSS file. (XML_ERR_NAME_REQUIRED at line 1, column 2) in C:\Inetpub\vhosts\theinvestorglobe.com\httpdocs\rss_fetch.inc on line 414

Warning: array_slice() expects parameter 1 to be array, null given in C:\Inetpub\vhosts\theinvestorglobe.com\httpdocs\corporations-news.php on line 440

Warning: Invalid argument supplied for foreach() in C:\Inetpub\vhosts\theinvestorglobe.com\httpdocs\corporations-news.php on line 441
 
Blogspot logo    Latest Posts from Random Roger
Serious Retirement Downsizing
Planning Advice From True Experts
James Altucher is Right, Retirees Shouldn?t Own A Home
?You?ll Be Stone Dead In A Moment?
Rock You Like A Hurricane
 
  Home

  Business News
  Personal Finance
  World News
  U.S. News
  China News
  India News
  Middle East News
  Technology
  Blogs

  Mergers and Acquisitions
  IPO (initial Public Offering)
  Bernard Madoff
  Geneal Motors Bankruptcy
  Food prices crisis

  Sitemap
  Gold
  Silver
  Platinum
  Palladium
  Rhodium

         

               
                 Copyright Leaderglobe.